Elevated EVL Methylation Level in the Normal Colon Mucosa Is a Potential Risk Biomarker for Developing Recurrent...

Area of Science:

• Gastroenterology
• Molecular Diagnostics
• Oncology

Background:

• Individuals with adenomatous colorectal polyps require surveillance for metachronous adenomas.
• Current surveillance methods lack precision in identifying patients who will develop recurrent adenomas.
• Novel biomarkers are needed to refine risk stratification for colorectal cancer surveillance.

Purpose of the Study:

• To evaluate altered EVL methylation as a potential biomarker for the risk of recurrent adenomas.
• To assess the association between EVL methylation levels and the risk of adenoma or colorectal cancer.
• To determine if EVL methylation can improve risk assignment for colorectal cancer surveillance.

Main Methods:

• EVL methylation (mEVL) was measured in normal colon mucosa from patients using a droplet digital PCR assay.
• The association between mEVL levels and adenoma/colorectal cancer risk was analyzed using three statistical models.
• Models adjusted for baseline characteristics and excluded patients with baseline colorectal cancer.

Main Results:

• Older age, never smoking, and baseline colorectal cancer were linked to higher mEVL levels.
• Each log base 10 increase in mEVL was associated with a significantly increased risk of adenoma(s) or cancer.
• Odds ratios ranged from 2.01 to 3.17 across different models, indicating a clear association.

Conclusions:

• EVL methylation levels in normal colon mucosa show potential as a biomarker for recurrent adenoma risk.
• These findings support the utility of EVL methylation for enhancing the accuracy of risk assessment in colorectal cancer surveillance.
• This biomarker could aid in personalizing surveillance strategies for patients with a history of colorectal polyps.